Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Oral Surgery
Reference49 articles.
1. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer;Vermorken;N Engl J Med,2007
2. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study;Guigay;Ann Oncol.,2015
3. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck;Bossi;Ann Oncol.,2017
4. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016
5. Surrogate endpoints for overall survival in locally advanced head and neck cancer : meta-analyses of individual patient;Michiels;Lancet Oncol,2009
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Recurrent Versus Metastatic Head and Neck Cancer: An Evolving Landscape and the Role of Immunotherapy;Biomedicines;2024-09-12
2. A novel prognostic score (HAMP) for head and neck cancer patients with single and multiple SBRT‐treated lung metastases derived from retrospective analyses of survival outcome;Head & Neck;2024-08-08
3. Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study;Radiotherapy and Oncology;2024-07
4. Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours;Journal of Clinical Medicine;2024-05-21
5. Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs;Precision Radiation Oncology;2024-05-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3